Hamer R J, Koedam J A, Beeser-Visser N H, Bertina R M, Van Mourik J A, Sixma J J
Eur J Biochem. 1987 Jul 1;166(1):37-43. doi: 10.1111/j.1432-1033.1987.tb13480.x.
The formation of a complex between factor VIII (FVIII) and von Willebrand factor (vWF) was studied using purified radiolabeled human FVIII and purified human vWF. A binding assay was developed in which vWF was coated on microtiter wells. FVIII was shown to bind specifically and reversibly to the immobilized vWF. At a coating of 70 pg vWF/well, binding was half-maximal at a FVIII concentration of 70 +/- 10 pM. In order to ascertain which part of FVIII interacted with vWF, eight monoclonal antibodies, directed against FVIII, were tested for their ability to inhibit FVIII-vWF interaction. One of the eight antibodies, CLB-CAg:58, inhibited binding completely. This antibody was demonstrated to react with the Mr-80,000 light chain of FVIII. Direct evidence for the involvement of this chain in vWF binding was obtained by studying the binding of isolated, radiolabeled FVIII heavy and light chains. In a typical experiment 23-30% of the radioactivity bound when the FVIII light chain was added and less than 1% when the FVIII heavy chain was added.
利用纯化的放射性标记人凝血因子VIII(FVIII)和纯化的人血管性血友病因子(vWF)研究了FVIII与vWF之间复合物的形成。开发了一种结合测定法,其中将vWF包被在微量滴定孔上。结果表明,FVIII能特异性且可逆地结合到固定化的vWF上。在每孔包被70 pg vWF时,FVIII浓度为70±10 pM时结合达到半数最大结合量。为了确定FVIII的哪一部分与vWF相互作用,测试了八种针对FVIII的单克隆抗体抑制FVIII-vWF相互作用的能力。八种抗体中的一种,CLB-CAg:58,完全抑制了结合。该抗体被证明与FVIII的Mr-80,000轻链发生反应。通过研究分离的放射性标记FVIII重链和轻链的结合,获得了该链参与vWF结合的直接证据。在一个典型实验中,加入FVIII轻链时结合的放射性为23%-30%,加入FVIII重链时结合的放射性小于1%。